Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2
Baraliakos X, Ramiro S, Magrey M, Rudwaleit M, Haroon N, Fleurinck C, Massow U, de Peyrecave N, Vaux T, Sarno A, Marzo-Ortega H, et al. (2023)
In: Abstract Supplement - 39th Scandinavian Congress of Rheumatology. Scandinavian Journal of Rheumatology , 52(Suppl. 131). Abingdon: Taylor & Francis : 73-74.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Baraliakos, X.;
Ramiro, S.;
Magrey, M.;
Rudwaleit, MartinUniBi;
Haroon, N.;
Fleurinck, C.;
Massow, U.;
de Peyrecave, N.;
Vaux, T.;
Sarno, A.;
Marzo-Ortega, H.;
Navarro-Compan, V.
Alle
Alle
Einrichtung
Stichworte
Clinical trial;
Randomised trial;
Spondyloarthritis
Erscheinungsjahr
2023
Titel des Konferenzbandes
Abstract Supplement - 39th Scandinavian Congress of Rheumatology
Serien- oder Zeitschriftentitel
Scandinavian Journal of Rheumatology
Band
52
Ausgabe
Suppl. 131
Seite(n)
73-74
Konferenz
39th Scandinavian Congress of Rheumatology: SCR2023
Konferenzort
Copenhagen
Konferenzdatum
2023-08-23 – 2023-08-26
ISSN
0300-9742
eISSN
1502-7732
Page URI
https://pub.uni-bielefeld.de/record/2984578
Zitieren
Baraliakos X, Ramiro S, Magrey M, et al. Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2. In: Abstract Supplement - 39th Scandinavian Congress of Rheumatology. Scandinavian Journal of Rheumatology . Vol 52. Abingdon: Taylor & Francis ; 2023: 73-74.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., et al. (2023). Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2. Abstract Supplement - 39th Scandinavian Congress of Rheumatology, Scandinavian Journal of Rheumatology , 52, 73-74. Abingdon: Taylor & Francis . https://doi.org/10.1080/03009742.2023.2233371
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, Martin, Haroon, N., Fleurinck, C., Massow, U., et al. 2023. “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2”. In Abstract Supplement - 39th Scandinavian Congress of Rheumatology, 52:73-74. Scandinavian Journal of Rheumatology . Abingdon: Taylor & Francis .
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., de Peyrecave, N., Vaux, T., Sarno, A., et al. (2023). “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2” in Abstract Supplement - 39th Scandinavian Congress of Rheumatology Scandinavian Journal of Rheumatology , vol. 52, (Abingdon: Taylor & Francis ), 73-74.
Baraliakos, X., et al., 2023. Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2. In Abstract Supplement - 39th Scandinavian Congress of Rheumatology. Scandinavian Journal of Rheumatology . no.52 Abingdon: Taylor & Francis , pp. 73-74.
X. Baraliakos, et al., “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2”, Abstract Supplement - 39th Scandinavian Congress of Rheumatology, Scandinavian Journal of Rheumatology , vol. 52, Abingdon: Taylor & Francis , 2023, pp.73-74.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., de Peyrecave, N., Vaux, T., Sarno, A., Marzo-Ortega, H., Navarro-Compan, V.: Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2. Abstract Supplement - 39th Scandinavian Congress of Rheumatology. Scandinavian Journal of Rheumatology . 52, p. 73-74. Taylor & Francis , Abingdon (2023).
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, Martin, Haroon, N., Fleurinck, C., Massow, U., de Peyrecave, N., Vaux, T., Sarno, A., Marzo-Ortega, H., and Navarro-Compan, V. “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2”. Abstract Supplement - 39th Scandinavian Congress of Rheumatology. Abingdon: Taylor & Francis , 2023.Vol. 52. Scandinavian Journal of Rheumatology . 73-74.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar